Karl Cahill
Founder at MOSS GENOMICS INC.
Net worth: 76 500 $ as of 2024-04-29
Profile
Karl Cahill is the founder and current Chief Executive Officer & Director of Moss Genomics, Inc., which is founded in 2018.
He was previously the Vice President-Investor Relations at Concordia Resource Corp.
from 2011 to 2012, and held the position of Head-Investor Relations at Raptor Pharmaceuticals Corp.
and Vice President-Investor Relations at AbraSilver Resource Corp.
Mr. Cahill completed his undergraduate degree at the University of Westminster.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
MOSS GENOMICS, INC.
5.70% | 2023-02-21 | 2,550,000 ( 5.70% ) | 76 500 $ | 2024-04-29 |
Karl Cahill active positions
Companies | Position | Start |
---|---|---|
MOSS GENOMICS INC. | Founder | 2018-09-24 |
Former positions of Karl Cahill
Companies | Position | End |
---|---|---|
Concordia Resource Corp.
Concordia Resource Corp. Other Metals/MineralsNon-Energy Minerals Concordia Resource Corp. is a junior exploration company with an emphasis on developing mineral deposits in Africa and South America. The company has an extensive exploration portfolio in the resource-endowed regions of Burkina Faso, Gabon, and the Democratic Republic of Congo. In addition, it holds interests in the La Providencia silver mine located in the Puna district of northwestern Argentina and also holds interests in the Cerro Amarillo-Cajon Grande copper-gold-molybdenum property located in the Malargüe District of Argentina. The company was founded on February 7, 2000 and is headquartered in Vancouver, Canada. | Investor Relations Contact | 2012-08-15 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Public Communications Contact | 2009-09-30 |
ABRASILVER RESOURCE CORP. | Investor Relations Contact | - |
Training of Karl Cahill
University of Westminster | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ABRASILVER RESOURCE CORP. | Non-Energy Minerals |
MOSS GENOMICS INC. | Health Technology |
Private companies | 2 |
---|---|
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
Concordia Resource Corp.
Concordia Resource Corp. Other Metals/MineralsNon-Energy Minerals Concordia Resource Corp. is a junior exploration company with an emphasis on developing mineral deposits in Africa and South America. The company has an extensive exploration portfolio in the resource-endowed regions of Burkina Faso, Gabon, and the Democratic Republic of Congo. In addition, it holds interests in the La Providencia silver mine located in the Puna district of northwestern Argentina and also holds interests in the Cerro Amarillo-Cajon Grande copper-gold-molybdenum property located in the Malargüe District of Argentina. The company was founded on February 7, 2000 and is headquartered in Vancouver, Canada. | Non-Energy Minerals |
- Stock Market
- Insiders
- Karl Cahill